Hepatocellular Carcinoma
Conditions
Brief summary
The purpose of this study is to evaluate the combination of Revlimid® (lenalidomide) and Nexavar® (sorafenib) for the treatment of hepatocellular carcinoma that can't be cured with surgery.
Interventions
DRUGLenalidomide
Escalating doses starting at 15 mg by mouth per day.
DRUGSorafenib
Fixed dose of 400 mg by mouth twice a day.
Sponsors
Celgene Corporation
Indiana University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Clinical or pathological diagnosis of unresectable hepatocellular carcinoma (HCC) based on radiologic criteria, elevated alpha fetoprotein and/or tissue biopsy * All previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least 28 days prior to treatment in this study * Child-Pugh Liver Function Class A/B9 * Eastern Cooperative Oncology Group (ECOG) performance status of \</= 2 at study entry * Laboratory test results within protocol-specific ranges * Disease free of prior malignancies for \>/= 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast. * All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist® (Revlimid is only available under a restricted distribution program called RevAssist.) * Females of childbearing potential must have two negative pregnancy tests before starting lenalidomide and must agree to use two methods of birth control and submit to pregnancy tests throughout the study. * Able to take aspirin daily as prophylactic anticoagulation * Age \>18 years at the time of signing the informed consent form * Life expectancy of at least 30 days
Exclusion criteria
* No serious medical condition, laboratory abnormality, or psychiatric illness (including no evidence of hepatic encephalopathy) that would prevent the subject from signing the informed consent form * No pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide) * No patients who have undergone surgical resection or received chemotherapy, percutaneous ethanol injection, radiation therapy or chemoembolization within 30 days prior to commencement of the study * No condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study * No use of any other experimental drug or therapy within 28 days of baseline * No known hypersensitivity to thalidomide * Patients who developed erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs will be excluded * No prior use of lenalidomide * No concurrent use of other anti-cancer agents or treatments * No known positivity for HIV or infectious hepatitis, type B-8/9 or C * No active infection not controlled effectively with antimicrobial or antiviral therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants with Dose Limiting Toxicities as a Measure of Safety of the combination of lenalidomide and sorafenib. | 2 years |
Countries
United States
Outcome results
None listed